Cancer Res Treat.  2016 Jan;48(1):142-152. 10.4143/crt.2014.227.

CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer

Affiliations
  • 1Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea. lwshmo@hanmail.net
  • 2Department of Pathology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea.
  • 3Department of Preventive Medicine and Environmental Health Center, Dong-A University College of Medicine, Busan, Korea.
  • 4Department of Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea.

Abstract

PURPOSE
The present study is to investigate the significance of CD44 variant 9 (CD44v9) expression as a biomarker in primary gastric cancer.
MATERIALS AND METHODS
With various gastric tissues, we performed immunohistochemical staining for CD44v9.
RESULTS
The positive expression rates for CD44v9 in tumor, including adenoma, early gastric cancer (EGC), and advanced gastric cancer (AGC), were higher than those in non-tumor tissues (p=0.003). In addition, the higher expression for CD44v9 was observed as the tissue becomes malignant. In the analysis of 333 gastric cancer tissues, we found that positive expression rates for CD44v9 were higher in the intestinal type or well differentiated gastric cancer than in the diffuse type or poorly differentiated gastric cancer. Interestingly, the positive expression indicated poor prognosis in EGC (5-year survival rate [5-YSR] in stage I, 81.7% vs. 95.2%; p=0.013), but not in AGC (5-YSR in stage II, 66.9% vs. 62.2%; p=0.821; 5-YSR in stage III, 34.5% vs. 32.0%; p=0.929). Moreover, strong positive expression (3+) showed a trend suggesting worse prognosis only in EGC, and it appeared to be associated with lymph node metastasis.
CONCLUSION
This study suggests that CD44v9 may be a good biomarker for prognosis prediction and for chemoprevention or biomarker-driven therapies only for EGC.

Keyword

CD44 variant; Biological markers; Stomach neoplasms; Survival; Prognosis

MeSH Terms

Adenoma
Biological Markers
Chemoprevention
Lymph Nodes
Neoplasm Metastasis
Prognosis
Stomach Neoplasms*
Survival Rate
Biological Markers
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error